Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash

Executive Summary

Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.

Related Content

Gottlieb's 2018 Generic Drug Approval Goal May Be In Doubt
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
USP Backs Down From Biologic Monograph Naming Plan Amid US FDA Objections
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
US FDA Vs. USP: Regulator Sees Biologic Product Monographs As Barrier To Biosimilars
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On
Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development
Generic Combination Products May Be Permitted Delivery Device Variations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts